Drugs / NI-0801
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01244607 | — | allergic contact dermatitis | Light Chain Bioscience - Novimmune SA | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01430429 | — | primary biliary cholangitis | Light Chain Bioscience - Novimmune SA | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NI-0801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01430429 ↗ |
| Action | Inhibit | “Anti-CXCL10 Monoclonal Antibody” NCT01430429 ↗ |
| Modality | Monoclonal antibody | “Anti-CXCL10 Monoclonal Antibody” NCT01430429 ↗ |
| Route | Intravenous | “single i.v. administration” NCT01244607 ↗ |
| Target | CXCL10 | “Anti-CXCL10 Monoclonal Antibody” NCT01430429 ↗ |